Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 13/20 | 0.54 |
| ▸ | MAPKAPK5 | Q8IW41 | 6/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | ROS1 | P08922 | 1/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.41 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25822696 | 0.90 | MAPKAPK5 (0.56) | SYKMAPKAPK5JAK2NTRK1ROS1 | |
| SCHEMBL25822683 | 0.89 | MAPKAPK5 (0.54) | SYKMAPKAPK5JAK2NTRK1ROS1 | |
| SCHEMBL25822675 | 0.88 | MAPKAPK5 (0.67) | SYKMAPKAPK5JAK2NTRK1ROS1 | |
| SCHEMBL25822689 | 0.86 | MAPKAPK5 (0.51) | SYKMAPKAPK5JAK2NTRK1ROS1 | |
| SCHEMBL25822741 | 0.86 | SYK (0.51) | SYKMAPKAPK5JAK2NTRK1ROS1 | |
| SCHEMBL25822684 | 0.85 | SYK (0.57) | SYKMAPKAPK5JAK2 | |
| SCHEMBL25822692 | 0.85 | MAPKAPK5 (0.51) | SYKMAPKAPK5JAK2NTRK1ROS1 | |
| SCHEMBL25822690 | 0.83 | MAPKAPK5 (0.47) | SYKMAPKAPK5JAK2NTRK1ROS1 | |
| SCHEMBL25822743 | 0.83 | SYK (0.48) | SYKMAPKAPK5 | |
| SCHEMBL25822681 | 0.81 | MAPKAPK5 (0.67) | SYKMAPKAPK5JAK2NTRK1ROS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219960-A1 | 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2 | OCUMENSION THERAPEUTICS (SUZHOU) CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219960-A1 | 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2 | OCUMENSION THERAPEUTICS (SUZHOU) CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219960-A1 | 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2 | SYK, KDR, FLT1 | SYK 1/4885MAPKAPK5 216/4885JAK2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.